Values of IL-6 and CRP in predicting the severity of coronavirus disease 2019: A meta-analysis

doi:10.3969/j.issn.1004-583X.2023.06.002

Abstract

Abstract:

Objective To investigate the clinical values of interleukin-6 (IL-6) and C-reactive protein (CRP) in predicting the severity of coronavirus disease 2019 (COVID-19). Methods Relevant studies about COVID-19 published between December 1, 2019 and January 16, 2021 were searched in online databases of Web of Science, Scopus, Embase, CNKI, Wanfang Data, VIP and CBM. Two investigators were independently responsible for literature screening and data extraction. RevMan5.4 software was used for meta-analysis. Resultss A total of 18 literatures involving 4286 COVID-19 patients were collected, including 1624 in severe group and 2662 in mild group. IL-6 ( SMD =0.92, 95% CI : 0.65-1.18, P <0.01) and CRP levels ( SMD =1.47, 95% CI : 1.03-1.91; P <0.01) in COVID-19 patients of severe group were significantly higher than those of mild group.Conclusion The increases in IL-6 and CRP levels are positively correlated with the severity of COVID-19, serving as inflammation markers for risk stratification of COVID-19, and providing meaningful references for clinical treatment.

Key words: COVID-19, interleukin-6, C-reactive protein, meta-analysis

CLC Number:

R563.12

Ni Yiyun, Liu Bin, Liang Qi, Li Xiaofeng. Values of IL-6 and CRP in predicting the severity of coronavirus disease 2019: A meta-analysis[J]. Clinical Focus, 2023, 38(6): 493-499.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.06.002

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I6/493

Figures/Tables 7

References 44

[1]	World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)[R]. 2020.
[2]	Coronavirus COVID-19 Global Cases[EB/OL]. https://covid19.who.int/.2021-04-09.
[3]	World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected., Interim Guidance[EB/OL]. https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf. 2021-04-09.
[4]	中华人民共和国国家卫生健康委员会. 关于印发新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL]. http://www.gov.cn/zhengce/zhengceku/202008/19/5535757/files/da89edf7cc9244fbb34ecf6c61df40bf.pdf.
[5]	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720. doi: 10.1056/NEJMoa2002032 URL
[6]	Liao XL, Chen H, Li Z, et al. Critical care for severe coronavirus disease 2019: a population-based study from a province with low case-fatality rate in China[J]. Chin Med J (Engl), 2020, 134(1):98-100.
[7]	Wu R, Ai S, Cai J, et al. Predictive model and risk factors for case fatality of COVID-19: A cohort of 21, 392 cases in Hubei, China[J]. Innovation (Camb), 2020, 1(2):100022.
[8]	Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Science, 2020, 368(6490):473-474. doi: 10.1126/science.abb8925 pmid: 32303591
[9]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X pmid: 32085846
[10]	Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab[J]. Proc Natl Acad Sci U S A, 2020, 117(20):10970-10975. doi: 10.1073/pnas.2005615117 URL
[11]	Campins L, Boixeda R, Perez-Cordon L, et al. Early tocilizumab treatment could improve survival among COVID-19 patients[J]. Clin Exp Rheumatol, 2020, 38(3):578. pmid: 32456769
[12]	Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study[J]. Lancet Rheumatol, 2020, 2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9 URL
[13]	Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study[J]. Immun Ageing, 2020, 17:22. doi: 10.1186/s12979-020-00194-w pmid: 32802142
[14]	Del VD, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival[J]. Nat Med, 2020, 26(10):1636-1643. doi: 10.1038/s41591-020-1051-9
[15]	Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19[J]. J Clin Virol, 2020, 127:104370. doi: 10.1016/j.jcv.2020.104370 URL
[16]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605. doi: 10.1007/s10654-010-9491-z pmid: 20652370
[17]	Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005, 5:13. pmid: 15840177
[18]	Liu L, Zheng Y, Cai L, et al. Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19[J]. Int J Lab Hematol, 2021, 43(2): 329-335. doi: 10.1111/ijlh.13374 pmid: 33099889
[19]	Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: Age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study[J]. Immun Ageing, 2020, 17:22. doi: 10.1186/s12979-020-00194-w pmid: 32802142
[20]	Ping Y, Xiang Y, Cheng D, et al. Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study[J]. BMC Infect Dis, 2020, 20(1):943. doi: 10.1186/s12879-020-05682-4 pmid: 33302889
[21]	Zhang L, Huang B, Xia H, et al. Retrospective analysis of clinical features in 134 coronavirus disease 2019 cases[J]. Epidemiol Infect, 2020, 148:e199. doi: 10.1017/S0950268820002010 URL
[22]	Xiaohong Y, Wanling H, Bing Y, et al. Changes of hematological and immunological parameters in COVID-19 patients[J]. Int J Hematol, 2020, 112 (4):553-559. doi: 10.1007/s12185-020-02930-w pmid: 32656638
[23]	Xiuqi W, Wenjuan Z, Jingyu S, et al. Hypolipidemia is associated with the severity of COVID-19[J]. J Clin Lipidol, 2020, 14(3) :297-304. doi: S1933-2874(20)30078-7 pmid: 32430154
[24]	Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: A retrospective cohort study[J]. Lancet Haematol, 2020, 7(9):e671-e678. doi: 10.1016/S2352-3026(20)30217-9 pmid: 32659214
[25]	Yang G, Changsong W, Kai K, et al. Cytokine storm may not be the chief culprit for the deterioration of COVID-19.[J]. Viral Immunol, 2020, 34(5):336-341. doi: 10.1089/vim.2020.0243 URL
[26]	Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: A multicentre retrospective study[J]. Epidemiol Infect, 2020, 148:e238. doi: 10.1017/S0950268820002332 URL
[27]	Lv Z, Cheng S, Le J, et al. Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: A retrospective cohort study[J]. Microbes Infect, 2020, 22(4-5):195-199. doi: S1286-4579(20)30085-X pmid: 32425649
[28]	Weili W, Zhongxiu Z, Xi L, et al. Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19[J]. J Clin Lab Anal, 2020, 34(10):e23547.
[29]	孙昀, 孙伟, 叶珺, 等. 168例新型冠状病毒肺炎患者临床特点及重症进展的影响因素分析[J]. 中华急诊医学杂志, 2020, 29(7):901-907.
[30]	杨秀红, 熊蓉, 胡述立, 等. 不同临床分型新型冠状病毒肺炎患者临床特征及抗体、核酸检测结果分析[J]. 实用心脑肺血管病杂志, 2020, 28(9):10-15.
[31]	魏剑浩, 郭倩, 李海聪, 等. 上海地区328例新型冠状病毒肺炎患者实验室数据分析[J]. 检验医学, 2020, 35(8):778-783.
[32]	吕宁, 陆加刚, 罗莎莎, 等. 生化及炎症指标在新型冠状病毒肺炎患者中的变化特征和应用价值[J]. 国际检验医学杂志, 2020, 41(20):2501-2505.
[33]	张永喜, 熊勇, 李新宇, 等. 新型冠状病毒肺炎出院患者203例的临床特点分析[J]. 中华传染病杂志, 2020, 38(8):472-478.
[34]	邹义龙, 余贻汉, 刘尧蓓, 等. 新型冠状病毒肺炎患者病情严重程度与临床特征的关系[J]. 广西医学, 2020, 42(13):1707-1712.
[35]	刘浩, 龙利, 张继波, 等. 新型冠状病毒肺炎患者血清胱抑素C与炎性因子水平变化及其相关性[J]. 天津医药, 2020, 48(8):753-756.
[36]	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11):1061-1069. doi: 10.1001/jama.2020.1585 pmid: 32031570
[37]	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062. doi: S0140-6736(20)30566-3 pmid: 32171076
[38]	Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study[J]. BMJ, 2020, 369:m1966.
[39]	Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19[J]. Am J Respir Crit Care Med, 2020, 201(11):1430-1434. doi: 10.1164/rccm.202003-0736LE URL
[40]	Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19[J]. Clin Infect Dis, 2021, 73(2):e445-e454. doi: 10.1093/cid/ciaa954 pmid: 32651997
[41]	Potere N, Di Nisio M, Cibelli D, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study[J]. Ann Rheum Dis, 2021, 80(2):1-2. doi: 10.1136/annrheumdis-2020-218243 pmid: 32647027
[42]	Price CC, Altice FL, Shyr Y, et al. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes[J]. Chest, 2020, 158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006 pmid: 32553536
[43]	Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study[J]. Immun Ageing, 2020, 17:22. doi: 10.1186/s12979-020-00194-w pmid: 32802142
[44]	Potere N, Di Nisio M, Cibelli D, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study[J]. Ann Rheum Dis, 2021, 80(2):1-2. doi: 10.1136/annrheumdis-2020-218243 pmid: 32647027

纳入研究	研究类型	研究来源	总样本量	性别 (男/女)	平均数/中位数年龄(岁)	NOS评分
Liu 2020^[18]	单中心回顾性研究	中国,武汉	294	162/132	56(39~67)	6
Jurado 2020^[19]	多中心回顾性研究	西班牙,多个地区	584	349/235	63.0±16.5	8
Yi 2020^[20]	单中心回顾性研究	中国,浙江	100	63/37	54(42~64)	6
Zhang 2020^[21]	单中心回顾性研究	中国,武汉	134	87/47	60.8±13.0	8
Yuan 2020^[22]	单中心回顾性研究	中国,福建	117	56/61	66(57~71)	6
Wei 2020^[23]	单中心回顾性研究	中国,武汉	565	289/276	66(59~72)	6
Liao 2020^[24]	多中心回顾性研究	中国,武汉	294	156/138	64(53~73)	8
Gao 2020^[25]	单中心回顾性研究	中国,黑龙江	126	66/60	64.9±12.8	6
Shi 2020^[26]	多中心回顾性研究	中国,陕西	134	65/69	46(34~58)	8
Lv 2020^[27]	单中心回顾性研究	中国,武汉	270	135/135	62.0±11.2	6
Wang 2020^[28]	单中心回顾性研究	中国,武汉	123	60/63	68(56~78)	8
孙昀 2020^[29]	多中心回顾性研究	中国,安徽	168	95/73	42.6±15.8	6
杨秀红 2020^[30]	单中心回顾性研究	中国,武汉	365	162/203	60.2±14.2	8
魏剑浩 2020^[31]	多中心回顾性研究	中国,上海	328	170/158	51.0±12.0	6
吕宁 2020^[32]	单中心回顾性研究	中国,深圳	246	119/127	44.0±13.2	6
张永喜 2020^[33]	单中心回顾性研究	中国,武汉	203	108/95	54.0±11.8	6
邹义龙 2020^[34]	单中心回顾性研究	中国,武汉	83	36/47	67.0±12.9	6
刘浩 2020^[35]	单中心回顾性研究	中国,武汉	152	84/68	56.5±13.5	6

纳入研究	研究类型	研究来源	总样本量	性别 (男/女)	平均数/中位数年龄(岁)	NOS评分
Liu 2020^[18]	单中心回顾性研究	中国,武汉	294	162/132	56(39~67)	6
Jurado 2020^[19]	多中心回顾性研究	西班牙,多个地区	584	349/235	63.0±16.5	8
Yi 2020^[20]	单中心回顾性研究	中国,浙江	100	63/37	54(42~64)	6
Zhang 2020^[21]	单中心回顾性研究	中国,武汉	134	87/47	60.8±13.0	8
Yuan 2020^[22]	单中心回顾性研究	中国,福建	117	56/61	66(57~71)	6
Wei 2020^[23]	单中心回顾性研究	中国,武汉	565	289/276	66(59~72)	6
Liao 2020^[24]	多中心回顾性研究	中国,武汉	294	156/138	64(53~73)	8
Gao 2020^[25]	单中心回顾性研究	中国,黑龙江	126	66/60	64.9±12.8	6
Shi 2020^[26]	多中心回顾性研究	中国,陕西	134	65/69	46(34~58)	8
Lv 2020^[27]	单中心回顾性研究	中国,武汉	270	135/135	62.0±11.2	6
Wang 2020^[28]	单中心回顾性研究	中国,武汉	123	60/63	68(56~78)	8
孙昀 2020^[29]	多中心回顾性研究	中国,安徽	168	95/73	42.6±15.8	6
杨秀红 2020^[30]	单中心回顾性研究	中国,武汉	365	162/203	60.2±14.2	8
魏剑浩 2020^[31]	多中心回顾性研究	中国,上海	328	170/158	51.0±12.0	6
吕宁 2020^[32]	单中心回顾性研究	中国,深圳	246	119/127	44.0±13.2	6
张永喜 2020^[33]	单中心回顾性研究	中国,武汉	203	108/95	54.0±11.8	6
邹义龙 2020^[34]	单中心回顾性研究	中国,武汉	83	36/47	67.0±12.9	6
刘浩 2020^[35]	单中心回顾性研究	中国,武汉	152	84/68	56.5±13.5	6